Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Mitochondrial basis of the anti-arrhythmic action of lidocaine and modulation by the n-6 to n-3 PUFA ratio of cardiac phospholipids

Abstract : The aim of this study was to evaluate the involvement of mitochondria in the mechanism of the anti-arrhythmic lidocaine. Rats were fed with a diet containing either n-6 polyunsaturated fatty acids (PUFAs, SSO group) or an equimolecular mixture of n-3 and n-6 PUFAs (FO group) for 8 weeks. The hearts were perfused according to the working mode using a medium with or without lidocaine 5 μm. They were then subjected to local ischemia (20 min) and reperfusion (30 min). Dietary n-3 PUFAs triggered the expected decrease in the n-6/n-3 PUFA ratio of cardiac phospholipids. Reperfusing the ischemic area favored the incidence of severe arrhythmias. Lidocaine treatment abolished almost completely reperfusion arrhythmias in the FO group, but did not display anti-arrhythmic properties in the SSO group. As it was indicated by measurements of the mitochondrial function, lidocaine seemed to favor mitochondrial calcium retention in the FO group, which might prevent cytosolic calcium spikes and reperfusion arrhythmias. In the SSO group, the resistance to lidocaine was associated with an aggravation of cellular damages. The mitochondrial calcium retention capacities were saturated, and lidocaine was unable to increase them, making the drug inefficient in preventing reperfusion arrhythmias.
Liste complète des métadonnées

https://hal-univ-bourgogne.archives-ouvertes.fr/hal-03434306
Contributeur : Catherine Vergely Connectez-vous pour contacter le contributeur
Soumis le : jeudi 18 novembre 2021 - 11:17:11
Dernière modification le : dimanche 5 décembre 2021 - 03:27:56

Lien texte intégral

Identifiants

Citation

Luc Demaison, Daniel Moreau, Fabienne Clauw, Catherine Vergely, Luc Rochette. Mitochondrial basis of the anti-arrhythmic action of lidocaine and modulation by the n-6 to n-3 PUFA ratio of cardiac phospholipids. Fundamental & Clinical Pharmacology, 2013, 27 (4), pp.373-386. ⟨10.1111/j.1472-8206.2012.01031.x⟩. ⟨hal-03434306⟩

Partager

Métriques

Consultations de la notice

38